Escherichia coli Infections Global Clinical Trials Review, H2, 2017

2017-08-11
Price :
Published : Aug-2017
No. of Pages : 67

Escherichia coli Infections Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Escherichia coli Infections Global Clinical Trials Review, H2, 2017” provides an overview of Escherichia coli Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Escherichia coli Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Helix BioPharma Corp (HBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada. Helix BioPharma Corp (......
$250

UCB SA (UCB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is......
$250

GeoVax Labs Inc (GOVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary GeoVax Labs Inc (GeoVax) is a clinical-stage biotechnology company, which develops human vaccines for diseases caused by HIV, cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company's vaccine development programs focus on human immunodeficiency virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. The company developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US. G......
$250

ICON Plc (ICLR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides a range of specialized services that span the entire lifecycle of product development. The company's service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, functional services provision, medical imaging, laboratory services, resourcing solutions and strategic support and tactical solutions for traditional, in vitro diagnostic, and software devices. The company offers research services in areas such as cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical......
$250

Adventist Health System – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Adventist Health System (AHS) is a faith based medical health care organization. It serves through hospitals, nursing facilities and home care agencies. The organization, through its technologies and clinical research provide general medical care and specialized care for more than four million patients every year. AHS provides various healthcare services such as cardiology center, diabetes, behavioral health, orthopedics, wound care, women's services, neurosurgery, eye care center, family practice, geriatrics care, pain medicine, pediatrics, psychology radiology center, rehab and many others. It also includes urgent care centers, home health and hospice agencies, and skilled nursing facilities. AHS is headquartered in Winter Park, Florida, the US. Adventist Health System - Pharma......
$250

AstraZeneca Plc (AZN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies and through distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, the UK. AstraZeneca Plc (AZN) - Pharmaceutica......
$250

Oragenics Inc (OGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Oragenics Inc (Oragenics) is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics against infectious disease and develops treatments for oral mucositis. The company develops a new class of potent gram-positive antibiotics which are called Lantibiotics for combating resistant bacterial infections. Its pipeline products include MU1140, being tested for healthcare associated infections caused by drug-resistant bacteria. The company develops other candidates and technologies in the oral care and weight loss areas which include AG013 for the treatment of oral mucositis in cancer patients; OG716 in preclinical phase for healthcare-associated infections; and LPT3-04 for weight loss. Oragenics is headquartered in Tampa, Florida, the US. O......
$250

Laboratoires Pierre Fabre SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company's products address the full spectrum of health care needs from pathologies such as cancer or atopical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands which include Derma, Galenic Klorane, Avene, Ducray, Rene Furterer, and others. Pierre Fabre is headquartered in Ile-de-France, France. Laboratoires Pier......
$250

Seattle Genetics Inc (SGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The company's lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate indicated for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics' product pipeline consists of SGN-CD33A (vadastuximab talirine) for acute myeloid leukemia (AML) and myelodysplastic syndrome; and ASG-22ME (enfortumab vedotin) for metastatic urothelial cancer. Its pipeline also comprises six antibody-drug conjugate (ADC) programs and two immuno-oncology programs in various clinical stages of development. It uses ADC and sugar-engineered antibody (SEA) technologies for......
$250

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company's product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US. Infinity Pharmaceu......
$250